Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

4CPS-068 Target therapy in non-small cell lung cancer (NSCLC): a retrospective analysis to guarantee the appropriateness of the prescriptions in our hospital

View Full Paper
Ask AI
Bookmark
Share

Authors

IMIsabella MartignoniESElena SantarossaLSLavinia Stefanizzi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Martignoni et al. (2024) studied this question.

synapsesocial.com/papers/68e7660bb6db6435876db99fhttps://doi.org/10.1136/ejhpharm-2024-eahp.172
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 14CPS-147 Osimertinib: a promising treatment for EGFR mutation-positive non-small-cell lung cancer2024
  2. 2EGFR and ALK Targeted Therapy Response in Non-Small Cell LungCancer Harboring Rare or Resistant Mutations: A Case Report andMolecular Insights2026
  3. 3195eP Real-world safety of ALK inhibitors in non-small cell lung cancer patients: A FAERS disproportionality analysis2026
  4. 4First- and second-line biomarker utilization in non-small cell lung cancer.2024
  5. 5Targeted therapeutic options in early and metastatic NSCLC-overview2024 · 43 citations